Skip to main content
Equibles
ALLO logo

ALLO · Allogene Therapeutics, Inc. · Metrics

Track ALLO — free

Use ALLO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALLO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.25 +0.00 (+0.00%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$431.86M
Shares
345.49M
Volume · Oct 23 8.4M Avg daily vol (3M) 5.79M

ALLO metrics

74 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.25
Market cap
$431.86M

Price action

20 metrics
Price change (1W)
-4.6%
Price change (30D)
-24.2%
Price change (3M)
-28.2%
Price change (6M)
-45.9%
Price change (YTD)
-8.8%
Price change (1Y)
+3.3%
Trailing year
Price change (5Y)
-92.1%
52-week high
$3.06
52-week low
$1.05
Change from 52-week high
-59.2%
Change from 52-week low
+19.0%
Annualized volatility
82.5%
Annualized volatility (3M)
58.1%
Beta
1.9
RSI (14D)
26.0
Price vs SMA 50
-26.7%
Price vs SMA 200
-37.2%
Avg volume (3M)
5.79M
Relative volume
1.5
Average dollar volume
$10.04M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
345.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
93.1×
reciprocal yield 1.1%
P / book
1.0
reciprocal yield 101.0%
FCF yield
-23.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-38.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$180.32M
Net income (TTM)
−$165.49M
Trailing 12 months
Diluted EPS (TTM)
$-0.67
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.72
EBITDA per diluted share (TTM)
$-0.68
Net income per diluted share (TTM)
$-0.67
Operating cash flow per diluted share (TTM)
$-0.41
Free cash flow per diluted share (TTM)
$-0.41
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.49
Stock compensation per diluted share (TTM)
$0.15
Book value per share
$1.28

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.64M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+50.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-37.9%
Return on assets
-30.1%
Debt / equity
—
Current ratio
10.7
EBITDA (TTM)
−$168.65M
Free cash flow (TTM)
−$102.60M
Quick ratio
10.7
Interest coverage
-138.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$38.63M
Latest balance sheet
Cash & equivalents
$38.63M
Total assets
$550.09M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$102.20M
Capital expenditures (TTM)
$402,000
R&D (TTM)
$122.52M
SG&A (TTM)
—
Stock compensation (TTM)
$37.49M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
210
13F filer change QoQ
+1
Institutional ownership
90.6%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
34.1%
Private-fund adviser ownership
27.5%
Active holders' share change QoQ
+66.8%
Holder tenure
13.6
Price vs estimated holder cost
-30.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.0%

Short interest

3 metrics
Short interest
16.1%
Latest settlement · 9.0 days to cover
Days to cover
9.0d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$62,958
Insider-sentiment score
51 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1737287 CUSIP 019770106 13F (30d) 23 filings 23 filers Visit website Investor relations